Details for Patent: 6,965,027
✉ Email this page to a colleague
Summary for Patent: 6,965,027
Title: | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1 -yl}-3-oxo-propionitrile citrate |
Abstract: | This invention relates to novel amorphous and crystallline forms of 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-pip eridin-1-yl}-3-oxo-propionitrile mono citrate salt, useful as inhibitors of protein kinases, and to their methods of preparation. |
Inventor(s): | Flanagan; Mark E. (Gales Ferry, CT), Li; Zheng J. (Quaker Hill, CT) |
Assignee: | Pfizer Inc. (New York, NY) |
Application Number: | 10/310,078 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,965,027 |
Patent Claim Types: see list of patent claims | Compound; Process; |
Drugs Protected by US Patent 6,965,027
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 6,965,027
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 037635 | ⤷ Try a Trial | |||
Austria | 497962 | ⤷ Try a Trial | |||
Australia | 2002348857 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |